Streetbeat News

CMPS

COMPASS Pathways plc

Industry

Medical - Care Facilities

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Open

5.15

Mkt cap

345M

Volume

3.6M

High

6.04

P/E Ratio

-2.31

52-wk high

12.75

Low

4.97

Div yield

N/A

52-wk low

4.05

A new study suggests suggestibility plays a role in the antidepressant effects of psilocybin therapy. The EU has allocated $7M for psychedelic research for various disorders. In Australia, the first psychedelic-assisted medical treatments in 50 years were provided. Incannex Healthcare's CEO discussed the company's role in psychedelic-assisted therapies on the Benzinga Psychedelics Podcast. Psychedelics stocks showed varied performance, with COMPASS Pathways, GH Research, and Incannex Healthcare closing higher, while others like Seelos Therapeutics and Enveric Biosciences closed lower. The AdvisorShares Psychedelics ETF (PSIL) closed at $1.43.

Portfolio Pulse from Lara Goldstein

January 27, 2024 | 3:00 pm

Compass Pathways has entered into a research collaboration agreement with Hackensack Meridian Health to develop a clinical model for its investigational COMP360 psilocybin treatment, pending FDA approval.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:17 pm

MAPS Public Benefit Corporation, a subsidiary of MAPS, has raised over $100M in Series A funding to support FDA approval of MDMA for PTSD treatment. The U.S. Department of Veterans Affairs is funding psychedelic research for veterans with PTSD and depression. A list of 30 influential figures in psychedelics for 2024 was highlighted. Psychedelics policy reform is advancing in 13 states. Psychedelics stocks and ETFs showed varied performance, with some like GH Research and Atai Life Sciences closing higher, while others like Clearmind Medicine saw a decline.

Portfolio Pulse from Lara Goldstein

January 12, 2024 | 9:55 pm

MAPS Public Benefit Corporation, a subsidiary of MAPS, has raised over $100 million in Series A funding to support FDA approval of MDMA for PTSD treatment. The company will rebrand as Lykos Therapeutics. The investment reflects growing interest in psychedelic treatments for mental illnesses. Atai Life Sciences, Compass Pathways, and Cybin Inc. are also advancing in the psychedelic space with significant investments and acquisitions.

Portfolio Pulse from Maureen Meehan

January 06, 2024 | 8:59 pm

The DEA has clarified that psychedelic mushroom spores are federally legal prior to germination as they do not contain psilocybin or psilocin. This clarification does not change the legal status of the spores, which are illegal in some states and may still be considered drug paraphernalia depending on their marketing or use. The DEA also discussed the legal status of marijuana seeds, delta-8 THC, and synthetic cannabinoids, indicating ongoing regulatory efforts and interpretations.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:41 pm

The American Medical Association has activated new CPT III codes for psychedelic-assisted therapies, which are temporary codes for emerging treatments. These codes will facilitate reimbursement and access to such therapies in the U.S. MAPS PBC and COMPASS Pathways (NASDAQ:CMPS) have been instrumental in developing these codes, which could lead to permanent CPT I codes if usage data supports it. MAPS PBC is awaiting FDA approval for MDMA therapy for PTSD, which could lead to DEA rescheduling of MDMA for medical use.

Portfolio Pulse from Lara Goldstein

January 03, 2024 | 10:50 pm

The article reports on the performance of psychedelic stocks from January 1, 2024. Cybin (CYBN) saw a gain, while ATAI Life Sciences (ATAI), Mind Medicine (MNMD), Compass Pathways (CMPS), and GH Research (GHRS) experienced losses.

Portfolio Pulse from Benzinga Insights

January 01, 2024 | 9:30 pm

President Biden signed the 2024 NDAA, which includes funding for clinical trials with psychedelics for active military members. Robert F. Kennedy Jr. expressed support for psychedelics in mental health treatment. Incannex Healthcare (NASDAQ:IXHL) is set to open Australia's first dedicated psychedelic-assisted therapy clinic. Psychedelics stocks showed varied performance, with COMPASS Pathways (NASDAQ:CMPS) closing at $8.75, and AdvisorShares Psychedelics ETF (NYSE:PSIL) closing at $1.42.

Portfolio Pulse from Lara Goldstein

December 27, 2023 | 3:09 pm

The debate on whether psychedelic treatments require psychotherapy is ongoing, with COMPASS Pathways' Dr. Guy Goodwin suggesting that the effects of psilocybin are primarily due to the drug itself, not psychotherapy. He argues for a neutral terminology and acknowledges the dose-response relationship of psilocybin. Meanwhile, Dr. Max Wolff of the MIND Foundation insists that psychotherapy is integral to effective psychedelic treatments, citing COMPASS' trial protocols that emphasize therapeutic processes and require therapists to be licensed healthcare practitioners. The discussion highlights differing views on the role of psychotherapy in psychedelic treatments within a clinical setting.

Portfolio Pulse from Lara Goldstein

December 19, 2023 | 7:44 pm

Compass Pathways (CMPS) stock is trading higher following Deutsche Bank's initiation of coverage with a Buy rating and a $16 price target.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.